Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

TuHURA Biosciences, Inc.

NASDAQ: HURA · Life Sciences · 8 alerts · CIK 1498382

Share price
$1.33Close, Nov 16
Market cap
$87.5M
Shares outstanding
65.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All TuHURA Biosciences, Inc. filings on SEC EDGAR ↗

8:01 AM ET 10-Q
Financial Results

TuHURA Biosciences Q3 2026 Results: Net Loss of $6.41M, Loss Narrows

TuHURA Biosciences reported a net loss of $23.2 million for the nine months ended September 30, 2026, compared to a $23.3 million loss in the prior year. The company significantly increased its total assets to $36.2 million, primarily through the capitalization of $6.9 million in revolving credit facility debt issuance costs and $2.9 million in prepaid R&D expenses.

Key figure
Net loss $6.41M
7:50 AM ET 8-K
Financial Results

TuHURA Biosciences Financial Results

TuHURA Biosciences reported financial results for the third quarter ended September 30, 2026, and provided updates on its Phase 3 immuno-oncology programs. The company highlighted positive preliminary data from its IFx-2.0 study in Merkel cell carcinoma and received FDA clearance to begin a Phase 1b study for its VISTA-inhibiting antibody, TBS-2025. Management noted that operations remain funded through a $50 million credit facility from its largest shareholder.

Term
Q3 2026

“We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months.”

Dr. James Bianco, President and Chief Executive Officer

“With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events.”

Dr. James Bianco, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.